What Most FemTech Products Get Wrong About Product-Market Fit

The PMF Framework Problem

Most product-market fit frameworks were designed for B2B SaaS. The canonical Sean Ellis question ("How disappointed would you be if you could no longer use this product?") is a blunt instrument that captures retention sentiment but misses the nuanced ways users relate to health products.

FemTech founders apply these frameworks to their products and get signals that look like weak PMF, when the reality is more complex: users have strong fit with the product's value proposition but unresolved concerns about trust, data privacy, clinical validity, or social stigma that prevent them from expressing that fit through standard metrics.

What's Different About Women's Health

The trust ceiling. Women's health products face trust barriers that productivity tools don't. Users may believe in the product's value proposition but withhold full engagement because they don't yet trust the company with their data, their diagnosis, or their vulnerability. Standard PMF surveys don't distinguish between "I don't find this valuable" and "I find this valuable but I don't trust you enough yet."

The clinical uncertainty problem. Many FemTech products exist in clinical grey zones — they're not medical devices, but they claim health benefits. Users who would otherwise be enthusiastic adopt a wait-and-see posture because they've been burned by wellness products that overpromised. This looks like low PMF but is actually unresolved credibility.

The social stigma factor. Conditions like PCOS, endometriosis, perimenopause, and fertility issues carry social weight. Users who find a product genuinely useful may still use it quietly, not share it, and not respond enthusiastically to NPS surveys — not because the product isn't meeting a need, but because the need itself isn't something they talk about openly.

What Actual PMF Looks Like in FemTech

When FemTech products find true PMF, the signals look different:

• Organic community formation: Users create peer groups, support communities, and information-sharing channels around the product without being prompted
• Clinician referrals: Healthcare providers start recommending the product to patients
• Longitudinal retention: Users stay through multiple hormonal cycles, seasons, or life stages — not just the initial engagement spike
• Stigma override: Users share the product despite the social sensitivity of the category, which signals that the value proposition is strong enough to override the stigma calculus

How to Build Toward Real PMF

Segment by trust, not just by demographics. Users who trust the product will behave differently from users who find it valuable but haven't yet crossed the trust threshold. Building for both cohorts simultaneously requires knowing which state each user is in.

Measure clinical engagement, not just product engagement. Are users following through on health recommendations? Are they logging data that requires vulnerability? These are stronger signals of real value than DAU or session length.

Design for longitudinal use from day one. FemTech PMF is not validated by a 30-day retention cohort. The conditions being addressed are chronic, cyclical, and lifelong. A product that users use for three years has PMF. A product that spikes in January and churns by March may not — even if January metrics look great.

The FemTech category has the potential to produce deeply impactful, highly retentive products. But getting there requires letting go of framework borrowed from categories where the user's relationship with the product is fundamentally less personal.